Antares pharma receives fda fast track designation for atrs-1902 for adrenal crisis rescue

Ewing, n.j., jan. 18, 2022 (globe newswire) -- antares pharma, inc. (nasdaq: atrs) (the “company”), a specialty pharmaceutical company, today announced that the u.s. food and drug administration (“fda”) has granted fast track designation for atrs-1902 for adrenal crisis rescue. the development program for atrs-1902 supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our vai™ novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.
ATRS Ratings Summary
ATRS Quant Ranking